



## VERIFI STUDY PUBLISHED IN PEER-REVIEWED JOURNAL CURRENT ONCOLOGY

**LUND, Sweden. Immunovia (IMMNOV: Nasdaq Stockholm), the pancreatic cancer diagnostics company, today announced the publication of the VERIFI clinical study in *Current Oncology*, a peer-reviewed medical journal dedicated to advancing cancer research and clinical practice.**

The article, "Validation of a serum-based biomarker signature for detection of early-stage pancreatic ductal adenocarcinoma," presents results from VERIFI, the second independent validation of Immunovia's PancreaSure test. The study demonstrates that PancreaSure has the ability to detect Stage I and II pancreatic cancer in high-risk individuals with 76.5% sensitivity and 87.8% specificity.

"Our results confirm that PancreaSure can reliably distinguish early-stage pancreatic cancer from high-risk controls," said Norma Palma PhD, VP Clinical and Medical Affairs at Immunovia. "This secondary validation study adds to the body of evidence of the test's strong performance in early detection of pancreatic cancer. Data from this study also helps us understand the potential role of the PancreaSure test in early detection of cancer in patients with pancreatic cysts."

The design of the VERIFI study largely mirrored that of the CLARITI study, the first clinical validation of the PancreaSure test. In VERIFI, strict age and gender-matching of case and control samples was performed to provide a clear evaluation of test performance.

Importantly, the VERIFI study included 145 patients with pancreatic cysts, including 62 individuals whose only risk factor for pancreatic cancer was the presence of one or more cysts. These individuals represent a particularly challenging group for clinicians and the VERIFI study builds on prior data indicating the accuracy of the PancreaSure test in patients with cysts.

"The publication in *Current Oncology* provides important independent validation of PancreaSure's performance," said Jeff Borcharding, CEO of Immunovia. "With two successful validation studies now published in peer-reviewed journals, we have established a strong foundation of scientific evidence supporting PancreaSure's role in early pancreatic cancer detection for high-risk populations."

**For further information, please contact**

Jeff Borcharding, CEO

[jeff.borcharding@immunovia.com](mailto:jeff.borcharding@immunovia.com)

**Immunovia in brief**

Immunovia AB is a diagnostic company whose mission is to increase survival rates for patients with pancreatic cancer through early detection. Immunovia is focused on the development and commercialization of simple blood-based testing to detect proteins and antibodies that indicate a high-risk individual has developed pancreatic cancer. Immunovia collaborates and engages with healthcare providers, leading experts and patient advocacy groups to make its test available to individuals at increased risk for pancreatic cancer.

USA is the world's largest market for detection of pancreatic cancer. The Company estimates that in the USA, 1.8 million individuals are at high-risk for pancreatic cancer and could benefit from annual surveillance testing.

Immunovia's shares (IMMNOV) are listed on Nasdaq Stockholm.

For more information, please visit [www.immunovia.com](http://www.immunovia.com).